Discovery teams are surrounded by more scientific information than ever before. The challenge is no longer simply accessing information; it is deciding what matters, what is emerging, and what is worth testing.

Intangia was built to help teams answer practical strategic questions: which targets are gaining momentum, which indications are underexplored, where is the competitive landscape becoming crowded, which modality may be best suited to a given opportunity, and where could a differentiated program be built?

The platform brings together scientific, clinical, patent, competitive, and company-level signals to generate prioritized opportunity maps. The goal is not to replace scientific judgment, but to give R&D, BD, and portfolio teams a faster and more structured way to identify opportunities that are worth validating experimentally.

Traditional literature reviews and competitive intelligence reports are often retrospective. They summarize what is already known. That is useful, but early discovery teams increasingly need a more forward-looking view: where is the field moving, and which opportunities may be emerging before they are obvious to everyone else?

General-purpose AI tools can summarize information very effectively, but they are not designed to track biomedical momentum across millions of concepts over time, connect signals across publications, patents, clinical trials, deals, companies, and modalities, or rank opportunities using a discovery-specific framework.

Intangia is designed for that purpose. We track targets, indications, modalities, mechanisms, and their co-occurrence patterns over time. We then apply scoring frameworks that consider scientific rationale, translational feasibility, competitive dynamics, development path, and commercial context.

The distinction is important. We are not just asking, "What does the literature say?" We are asking, "Which opportunities are becoming actionable, why now, and what evidence supports testing them?"

This is one of the most important questions. In discovery, it is not enough to produce a long list of plausible ideas. Teams need to know whether a shortlist is enriched for opportunities that have a higher probability of progressing.

One way we are addressing this is through retrospective validation. We look back at historical time points using only the information that would have been available at that time, and we ask whether the platform would have identified or ranked opportunities that later progressed into clinical development, BD transactions, or other meaningful development milestones.

This helps us move from an "interesting signal" to a more disciplined probability-of-success framework. For example, instead of assuming that every target or indication has equal value, we can test whether top-ranked opportunities are meaningfully enriched for real-world progression.

That is particularly important for clients making portfolio, BD, or R&D investment decisions. They are not trying to pursue every possible idea. They need a small number of high-conviction opportunities where the biology, timing, competitive landscape, and feasibility all support a decision to invest further.

The industry is moving toward more distributed innovation. Many promising ideas now come from small biotech, academic groups, global innovation hubs, and investor-backed company creation models. At the same time, these teams often have limited bandwidth and need to make high-quality decisions quickly.

That creates a need for more efficient discovery infrastructure. Teams want to know which targets, indications, or assets deserve attention, but they also need a practical route to validate those ideas. It is not enough to identify a white space. You need to understand whether the opportunity is biologically credible, differentiated, experimentally testable, and commercially relevant.

This is where Intangia can help. We provide a structured way to surface and prioritize opportunities across scientific, clinical, competitive, and translational signals. That can support R&D strategy, business development, portfolio planning, and investor-backed company creation.

We also see a major opportunity in connecting this intelligence with global execution networks. Intangia has been spending significant time in China and building strong relationships with local partners, where we see a unique ability to identify, validate, and advance opportunities at a speed that is difficult to match elsewhere. For biotech, pharma, and VC-backed teams, that can create a much faster path from idea to validated program.

When combined with BioDuro's capabilities, the opportunity becomes even stronger: clients can move from intelligence to execution more efficiently, with a clearer path from hypothesis to experimental validation.

The most valuable output is not simply a ranked list. It is a clear rationale for what to do next.

For each opportunity, we aim to explain why the signal is emerging, what evidence supports it, which competitors or academic groups are active, which indications or patient populations may be most relevant, and what uncertainties need to be resolved. From there, the next question is usually experimental: what assay, model, biomarker, or validation package would give the client confidence to move forward?

This is where the connection with BioDuro becomes highly relevant. Intangia can help identify and prioritize the opportunity, while BioDuro can help design and execute the experiments needed to validate it. That could include biology assays, translational studies, DMPK, chemistry, or other integrated discovery work depending on the question.

In other words, the workflow can move from "what should we test?" to "how should we test it?" and then to "what data do we need to make a decision?"

Many clients have strong internal teams, but they still face the same bottleneck: identifying the right opportunity early, pressure-testing it quickly, and deciding whether to invest further.

Together, Intangia and BioDuro can support that process from hypothesis generation through experimental validation. Intangia can map the scientific and competitive landscape, identify emerging target or indication opportunities, and prioritize them using evidence-based scoring. BioDuro can then help clients translate those insights into practical experimental plans and high-quality data.

This also reflects Intangia's broader ambition. We are not only building a platform to generate insights; we are building a model to help partners advance selected, high-confidence opportunities. We expect to announce collaborations around co-developing programmes with partners, where pharma and VC networks can help create multiple paths for value creation — including partnering, licensing, or potentially forming new companies around validated opportunities.

For clients, the value is a more integrated discovery workflow: fewer blind spots, faster prioritization, and a clearer path from insight to experiment. Ultimately, the goal is to help teams make better discovery decisions with more confidence — by combining AI-driven intelligence with BioDuro's global discovery execution capabilities.